Fundz

InMed Pharmaceuticals Completes Acquisition of Mentari

PUBLIC · INMNov 16, 2026

Acquiring Company

InMed Pharmaceuticals

Acquired Company

Mentari

VancouverHealthcareBiotechnologyHealth Care

Description

InMed Pharmaceuticals Inc. has completed its acquisition of Mentari, enhancing its portfolio in cannabinoid-based therapies. This strategic acquisition aims to bolster InMed's capabilities in addressing rare diseases. Financial statements and further details regarding the operations of Mentari have been included in the company's filings.

Quick answer

InMed Pharmaceuticals is acquiring Mentari, announced November 16, 2026. InMed Pharmaceuticals is based in Vancouver, British Columbia, Canada.

How much did InMed Pharmaceuticals pay for Mentari?
The deal value was not disclosed.
What does InMed Pharmaceuticals do?
InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids.
Where are InMed Pharmaceuticals and Mentari based?
InMed Pharmaceuticals is based in Vancouver, British Columbia, Canada.

Source: Fundz verified event record.

Other recent acquisitions in Healthcare and Biotechnology

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at InMed Pharmaceuticals, and when

When InMed Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day InMed Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at InMed Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at InMed Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

InMed Pharmaceuticals

Location

815 W. HASTINGS STREET

Vancouver, British Columbia, Canada

About

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. Nasdaq: INM

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment InMed Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for InMed Pharmaceuticals's next move

Learn about Strategic plan

Frequently asked

Who acquired Mentari?

Mentari was acquired by InMed Pharmaceuticals, based in Vancouver. The deal was reported on November 16, 2026. InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. InMed Pharmaceuticals is publicly traded (INM) and operates in Healthcare.

When did InMed Pharmaceuticals acquire Mentari?

InMed Pharmaceuticals's acquisition of Mentari was reported on November 16, 2026. InMed Pharmaceuticals Inc. has completed its acquisition of Mentari, enhancing its portfolio in cannabinoid-based therapies. This strategic acquisition aims to bolster InMed's capabilities in addressing rare diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Mentari do?

Mentari is a biotechnology firm focused on advancing unique therapeutic solutions. They aim to address significant unmet medical needs through innovative biopharmaceutical development. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.